Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q4 2018 Results - Earnings Call Transcript

|
About: Infinity Pharmaceuticals, Inc. (INFI)
by: SA Transcripts
Subscribers Only
Earning Call Audio

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Q4 2018 Results Earnings Conference Call March 14, 2019 8:00 AM ET

Company Participants

Jayne Kauffman - Senior Executive Coordinator

Adelene Perkins - CEO

Samuel Agresta - CMO

Lawrence Bloch - President

Jeffery Kutok - Chief Scientific Officer

Conference Call Participants

Katherine Xu - William Blair

Tessa Romero - JP Morgan

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals Conference Call to discuss the Company's Financial Results for the Full Year 2018. My name is Candice, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at Infinity's request.

Now, I would like to introduce your host for today's call, Jayne Kauffman. Please go ahead.

Jayne Kauffman

Thank you, Candice, and good morning, everyone. Welcome to today's call to discuss our recent business progress and review our full year 2018 financial results. With me here today are Adelene Perkins, Chief Executive Officer; Larry Bloch, President; Dr. Sam Agresta, Chief Medical Officer; and Dr. Jeff Kutok, our Chief Scientific Officer.

We will open up the call for Q&A following our remarks. The press release issued this morning details our results and is available on our website at infi.com. Please note that during this call, we may make forward-looking statements about our future expectations and plans, including clinical development objectives, the therapeutic potential of our product candidates, our strategic plans and strategies, and financial projections.

Our actual results may differ materially from what we project today due to a number of important factors, including the considerations described in the Risk Factors section of our annual report on Form 10-K for the full year 2018 and in other filings we make with the SEC.

These forward-looking statements represent our views only as of today, and we caution you that we may not make updates to them in the future, whether as a result of new information, future events or otherwise.

Now, I'd like to turn the call over to Adelene.

Adelene Perkins

Thanks, Jayne, and thank you to everyone for joining us. We're excited to review the progress we made during 2018 and highlight several recent developments that significantly advanced the value creation strategy we outlined at the beginning of the year.


Value creation at Infinity will be driven by compelling clinical data with IPI-549 in areas of significant unmet patient need and access to the resources necessary to generate this data. MARIO-3, the study we announced this morning with Roche/Genentech is a very important milestone in enabling the generation of this data while accessing key resources.

We're thrilled to be adding a clinical collaboration with another top tier oncology company in leveraging IPI-549’s unique mechanism of action in reprogramming macrophages to enhance outcomes for patients with triple negative breast cancer or TNBC and renal cell cancer or RCC.

A core component of our clinical strategy is to move IPI-549 into early lines of therapy with novel combination. In MARIO-3 we are adding IPI-549 to a newly approved and emerging standard-of-care in the frontline setting.

Last week, the FDA granted accelerated approval for the combination of Tecentriq, Roche's PD-L1 inhibitor and the chemotherapy Abraxane or nab-paclitaxel in treating front-line PD-L1 positive triple negative breast cancer patients.

The approval was based on results of the IMpassion130 study, and this combination is the first immuno-oncology regimen to be approved in TNBC, is widely accepted to become a new standard-of-care. Immediately on the heels of this approval, we are very pleased to be adding IPI-549 to Tecentriq and Abraxane which could lead to a truly transformative therapy for front-line patients with TNBC.

We're also enthusiastic about the potential for mechanistic synergy and combining IPI-549, Tecentriq and the VEGF inhibitor Avastin in front-line patients with renal cell carcinoma. There's an equally significant unmet need for RCC patients and an equally compelling mechanistic rationale for the combination. Jeff will describe the mechanistic and preclinical rationale for both these triple combination front-line therapies in more detail. After which Sam will describe the design and objective of the MARIO-3 clinical study, which we expect to initiate in the third quarter of this year.

The data that will be generated in the front-line with MARIO-3 complements the data that will be generated in the second-line with MARIO-275. MARIO-275 being conducted in collaboration with BMS is a randomized Phase 2 study evaluating IPI-549 and Opdivo or nivolumab in immuno-oncology naïve patients with urothelial cancer. MARIO-275 integrates findings from two studies: BMS' CheckMate 275 study in urothelial cancer patients with Opdivo monotherapy, which showed that lower overall survival was strongly correlated with high levels of myeloid-derived suppressor cells or MDSCs, and our MARIO-1 study in which MDSCs were reduced in the majority of patients following treatment with IPI-549.

Given the role of IPI-549 in reducing MDSCs, our goal is to demonstrate that the combination of IPI-549 and Opdivo improves outcomes in these patients. MARIO-275 will be initiated in the second quarter of this year.

In 2019, we will also be initiating our study in collaboration with Arcus, evaluating IPI-549 with Arcus' adenosine inhibitor and chemotherapy in patients with relapsed/refractory TNBC.

Finally, MARIO-1 data continue to mature in PD-1 resistant patients including our expanded cohort of PD-1 resistant melanoma patients and we look forward to sharing findings that are relevant to MARIO-3, MARIO-275 or that may inform future studies with IPI-549.

Compelling data are the cornerstone of value creation and we have a strong portfolio of studies across several lines of therapy including front-line, immuno-oncology naïve and relapsed/refractory setting across several indications, including urothelial cancer, triple negative breast cancer, renal cell cancer and melanoma with several novel double and triple therapy regimens with three world class partners with whom we will generate data in over 500 patients.

Our business development strategy has been to establish arm’s length collaborations without licensing rights to IPI-549 such that any future strategic collaborations around the program will be data driven and will affect the value that we create by the breadth and depth of our clinical program.

Our number one priority in 2019 is execution to deliver on the promise of these studies and the team is working hard to initiate and enroll these studies as rapidly as possible. Generating this data requires considerable resources and we have focused on accessing non-dilutive capital.

In late 2016, we made the strategic decision to outlicense duvelisib now approved as COPIKTRA to Verastem so that we could focus Infinity and our resources on the advancement of IPI-549. We have realized considerable financial benefits from this outlicensing strategy having received a $6 million milestone in 2017, a $22 million approval milestone in November of 2018 and having announced last week the monetization of our royalty stream on duvelisib for $22.5 million. The proceeds from duvelisib since November of 2018 together with contribution and kind of combination drugs from Roche/Genentech and BMS during the same period representing savings of approximately $20 million, have resulted in access to the equivalent of over $60 million of non-dilutive capital over the last two quarters alone.

Importantly, these proceeds have enabled the significant expansion of the clinical development of IPI-549, while extending our cash runway into the second half of 2020 which Larry will review in more detail.

Looking further into 2019, we're eager to build on the momentum we established during 2018 and in the first few months of this year to deliver on the promise of IPI-549. We remain driven by the magnitude of unmet need for better treatment options for people with cancer and the role that IPI-549 as a first-in-class therapy can play in addressing them. The more we work on IPI-549 alone and in collaboration with world-class partners, the more confident we are in its potential to have a transformative impact.

With that, I'll turn the call over to Jeff.

Jeffery Kutok

Thanks, Adelene. As an important part of our development of IPI-549 as a first and best-in-class drug candidate, we remain committed to optimizing our understanding of the biology of IPI-549 both as a monotherapy and in combination with immune checkpoint inhibitors as well as other agents.

Our preclinical work and the in-depth analysis of translational data from our existing MARIO-1 study has contributed to the initiation of new trials, including the previously announced MARIO-275 in collaboration with BMS and today's announcement of MARIO-3 in collaboration with Roche/Genentech.

We’ve spoken in detail about the effect of IPI-549 on reducing MDSC levels, which provided a rationale to combine with Opdivo in urothelial cancer, given the association of shorter survival with high baseline MDSC levels demonstrated in CheckMate 275 at last year's AACR Meeting.

In addition, preclinical data recently presented by Arcus Bioscience at a Keystone Symposia Meeting focused on mechanisms of immune-based therapy in cancer, showed that IPI-549 synergized with their adenosine receptor inhibitor AB928 in settings with high levels of adenosine. We're therefore excited to see the clinical effects of IPI-549 combined with AB928 and chemotherapy in relapsed/refractory triple negative breast cancer, a collaborative study with Arcus that is expected to start in the second half of 2019.

I addition, we have other preclinical collaborations ongoing in various tumor models to support the combination of IPI-549 with other mechanisms of immune-suppression or immune activation and to establish the best targets for further development and expansion.

Lastly, I'd like to focus on the mechanistic rationale for pursuing the triple combinations of IPI-549 with the checkpoint inhibitor in either chemotherapy or in anti-angiogenic in front-line TNBC and renal cell cancer as part of our new clinical collaboration MARIO-3 with Roche/Genentech.

First, with respect to the combination of IPI-549 and the checkpoint inhibitor Tecentriq, we published extensive preclinical data in multiple cancer models that IPI-549 reprograms macrophages from a pro-tumor immune suppressive function to an anti-tumor immune activating function and in both augment the activity of checkpoint inhibitor therapies, as well as recover the activity of a checkpoint inhibitor resisted model.


Second, with respect to combining IPI-549 with chemotherapy or anti-angiogenics I well described in the literature that tumor-associated immune suppressive and pro-growth M2 macrophages accumulate in tumors after chemotherapy or anti-angiogenics. And therefore, contribute to tumor re-growth and revascularization after these treatments. Targeting these newly recruited macrophages of IPI-549 could therefore reverse the effects.

To that end we've previously presented that murine tumors treated with IPI-549 after chemotherapy, showed inhibition of tumor re-growth compared to no therapy. And we have internal data that the combination of anti-angiogenic with IPI-549 shows enhanced inhibition of tumor growth. These data provide a clear rationale for treating with IPI-549 and Tecentriq in combination with either Abraxane or Avastin to target the tumor and the tumor microenvironment.

I will now turn it over to Sam, who will discuss more on the clinical relevance of these combination studies.

Samuel Agresta

Thanks, Jeff. 2019 will be a really exciting year of execution for us at Infinity as we continue to broaden the development of IPI-549 and expand its therapeutic potential by: one, moving into the IO naïve second-line setting with MARIO-275 in urothelial cancer in collaboration with BMS; Two, exploring novel model combinations in relapsed/refractory triple negative breast cancer with Arcus; And three, advancing the front-line in triple negative breast cancer and renal cell cancer with Roche/Genentech.

The data we have generated to-date with MARIO-1 supports that IPI-549 is a potentially transformative first-in-class drug candidate that can provide significant clinical benefit to patients with advanced solid tumors.

In November 2018, at the SITC Annual Meeting, we reported data from the combination expansion portion of our MARIO-1 study showing that IPI-549 and Opdivo can reverse resistance to a immediate prior checkpoint inhibitor therapy.

We also showed early signs of clinical activity in chemotherapy resistant triple negative breast cancer, a tumor type that is intrinsically resistant to checkpoint inhibitors which has informed the MARIO-3 study announced this morning. The totality of the data from MARIO-1 supports that IPI-549 is safe and active in monotherapy and in combination with Opdivo, and notably, in late-line patients who have progressed on immediate prior checkpoint inhibitor treatment. The clinical activity is on target associated with a reduction in immune suppression and an increase in immune activation.

We will continue to follow the outputs from MARIO-1 to inform our development strategy. MARIO-275 is our randomized study designed to evaluate IPI-549 plus Opdivo as compared to single agent Opdivo in advanced IO naïve urothelial cancer patients. We are conducting this study in collaboration with Bristol-Myers Squibb who obtained approval of single agent Opdivo based on the single arm Phase 2 study CheckMate 275.

MARIO-275 is a follow on study to CheckMate 275 and is built upon our foundational scientific hypothesis that MDSCs play an important role in limiting the effectiveness of many immunotherapies. A retrospective analysis of CheckMate 275 showed that high levels of MDSCs were associated with a shorter overall survival in patients treated with Opdivo alone. This, along with our data from MARIO-1 demonstrating the treatment with IPI-549 is associated with the reduction in MDSC levels, serves as the rationale for this study.

We are excited that our collaboration with Arcus is moving forward. Together, we are evaluating the addition of IPI-549 to their dual adenosine receptor antagonist and chemotherapy in relapsed/refractory triple negative breast cancer.

We also just announced a new clinical collaboration with Roche/Genentech that will evaluate IPI-549 in front-line triple negative breast cancer and renal cell cancer as Adelene outlined. Approximately 100 treatment naïve patients will be evaluated in total across three different cohorts: Locally advanced and/or metastatic triple negative breast cancer with PD-L1 positive disease; locally advanced and/or metastatic triple negative breast cancer with PD-L1 negative disease; and locally advanced and/or metastatic renal cell cancer agnostic of PD-L1 status.

We are excited to be advancing IPI-549 into the front-line setting and these indications in collaboration with colleagues at Roche/Genentech. Data from IMpassion130 and IMmotion151 support the benefit of Tecentriq plus Abraxane as well as the benefit of Tecentriq plus Avastin in front-line triple negative breast cancer and renal cell cancer respectively.

Just last week the FDA granted accelerated approval for Tecentriq plus Abraxane PD-L1 positive front-line locally advanced and/or metastatic triple negative breast cancer. In our MARIO-3 study we intend to evaluate how the addition of IPI-549 can improve upon the data observed from these studies including a higher conversion of responders to complete remissions as well as improved durability. We will also evaluate the clinical benefit as it is associated with MDSC levels.

The results from this study will inform our future clinical development plans in these indications. 2019 will be a year of execution as we are now expanding into new indications and earlier lines of therapy with improved and potentially transformative novel regimens. We look forward to the readouts of these studies and the potential to help a broad spectrum of patients.

I would now like to turn the call over to Larry.

Lawrence Bloch

Thank you, Sam. As you heard from Adelene, Jeff and Sam, we're really proud with the progress we've made in 2018 and are absolutely focused on and committed to continue to build on this progress in the year ahead.

Early this week we were pleased to receive $20 million in net proceeds from HealthCare Royalty Partners for the monetization of COPIKTRA or duvelisib royalties which we announced last week. These funds combined with our consistent fiscal discipline ensures that we will have the key resources in place to execute on the expanded IPI-549 development plan that we announced today.

As of December 31, 2018, we had total cash, cash equivalents and available for sale securities of $58.6 million, compared to $57.6 million at December 31, 2017. We recorded $22.1 million in revenue during 2018, related to the amount from Verastem for the approval by the FDA of duvelisib. This compared to $6 million at this time last year, which was related to the amounts received from Verastem for the successful completion of the duvelisib DUO study.

Revenue reported for 2018 does not reflect the recent duvelisib royalty monetization would HealthCare Royalty Partners. R&D expense for 2018 was $19.8 million, compared to $20.8 million for the same period in 2017. General and administrative expense was $14.2 million for 2018, compared to $21.6 million for same period in 2017. And the decrease in general and administrative expense was primarily due to reduction in bonus and stock compensation.

Net loss for 2018 was $11.3 million, or a basic and diluted loss per common share of $0.20, compared to a net loss of $41.8 million, or a basic and diluted loss per common share of $0.83 for the same period in 2017.

We expect 2019 net loss to range from $30 million to $40 million and we expect to end 2019 with a cash and investment balance ranging from $40 million to $50 million. Based on our current operating plans, which exclude additional funding or business development activities, we anticipate that our existing cash, cash equivalents and available-for-sale securities will provide cash runway well into second half of 2020. This cash runway includes potential $2 million milestone payment from PellePharm, the private company upon initiation of a Phase 3 study for the hedgehog inhibitor program, which we licensed to them in 2013.

And I’d like to finish by reviewing our key 2018 accomplishments, recent developments, as well as our plan for 2019. In 2018, we delivered on our key objectives for the year, which included reporting positive data from the monotherapy expansion in combination with dose escalation portions of our MARIO-1 study and reporting positive data updated from the combination expansion portion of the trial. We did this while also expanding our melanoma and triple negative breast cancer combination cohorts and announcing our clinical collaboration with Bristol-Myers Squibb, Arcus and now the Roche/Genentech collaboration.

In addition of MARIO-3 study in collaboration with Roche/Genentech, the Arcus collaboration and the MARIO-275 study in collaboration with BMS to the ongoing MARIO-1 study in collaboration with BMS, Infinity will be evaluating IPI-549 in the anti-PD-1 refractory, the IO naïve and the front-line settings in the total of over 500 patients, while also ensuring a cash runway well into the second half of 2020 and retaining all clinical control and commercial rights of IPI-549. We look forward to updating you on our continuing progress during the course of this year.

At this time, we can open the call for questions. Operator?

Question-and-Answer Session

Operator

[Operator Instructions]. And our first question comes from Katherine Xu, William Blair. Your line is now open.

Katherine Xu

So can you remind us the MARIO-1 in your TNBC patients, any follow-up and details on that? And also, did you see -- were they PD-L1 positive or negative? And also for RCC, I was just wondering the choice of Tecentriq and Avastin because the front-line space is getting quite crowded with the most recently KEYNOTE-426’s success. So the choice there is, is because it's just a convenient with the supply agreement of Tecentriq with Roche or other rationale?

And the other question is, have you found from MARIO-1a sort of the rare cancer to go forward so that -- of course right now you're targeting quite major indication from rare cancer to go forward, so that it would take less time and less resources and to get approvals some kind of low hanging fruit, have you been able to identify such special indication? Thank you.

Adelene Perkins

Okay so Katherine, why don't we go through each of your three questions? First on the triple negative breast cancer. As you know in MARIO-1 one of the explicit purposes was to look for patients that would not be expected to respond to nivolumab alone. So we had the both three cohorts of patients in who had immediately progressed on a checkpoint inhibitor and then the triple negative relapsed/refractory because those patients typically don't respond to Opdivo alone. So we presented at SITC, activity, and I'll let Sam elaborate more on that. But what we were very encouraged by is seeing activity there where you wouldn't expect it with Opdivo and that was as a foundation in our discussions with Roche/Genentech that got them enthused to do this collaboration.

Sam, you want to elaborate?

Samuel Agresta

Sure. This is Sam. What we presented at SITC was early data in the cohorts, and I'll remind you that you that we did see a nice near partial remission in a very late-line triple negative breast cancer patient. Remember that data was caught in October of 2018, so we'll continue to look at that cohort, that cohort will continue to mature. And in conversations with Roche/Genentech, we certainly shared the information that we have presented and more to outline the way path forward.

Adelene Perkins

And then on your earlier question with respect to renal cell cancer, Jeff described the rationale for combining with a VEGF inhibitor. And then we worked closely with the team at Roche/Genentech to determine what are the best settings to evaluate that combination and there remains a significant need for better treatment for patients with renal cell cancer. And so part of our clinical development is to leverage findings we have out of MARIO-1 but also to expand it. And so given the strong mechanistic rationale for combining with Tecentriq and Avastin and 549, we together decided that renal cell was a good place to test that hypothesis where there remains a significant need.

Samuel Agresta

Yes, and this is a Sam. Again one of the key assets of 549 is the safety profile. So as we think about the changing paradigm and standard-of-cares in renal cell cancer, in this case, it makes preclinical sense and it makes clinical sense given the safety profile of drug and the activity to be able to combine in front-line patients. So we look forward to starting that Phase 2 study.

Adelene Perkins

And then your third question was about rare cancers and whether we could pave a path to an approval. And I'm going to turn this over to Sam, but I'll remind you one of the reasons we were so excited to have Sam join the effort is, he has a pretty extraordinary track record in working very closely with the FDA and when he was Agios got both IDHiFA and TIBSOVO approved on single arm Phase 1 data. So Sam is all about any trial can be approved if you're really showing a significant benefit in a well designed study and a well designed patient population. And he has certainly brought that perspective to our development of 549. And Sam?

Samuel Agresta

So this is Sam and I -- again I think rare versus opportunity for patients are probably the same. So what I would consider the opportunity in -- for MARIO-1 is the unmet need -- the opportunity to allow for retreatment with checkpoint inhibitors in late-line cancers. That could be in several different indications. The FDA has precedents where they've given labels to checkpoint inhibitors that are agnostic of histologic indications. So TNBC high cohort, the cohorts where we mandate an immediate prior checkpoint inhibitor resistance, are opportunities for us to help patients very quickly. So we’re looking forward to see that data maturing.

Operator

And your next question comes from Anupam Rama of JP Morgan. Your line is now open.

Tessa Romero

Hi. This is Tessa on for Anupam this morning. Thank you for taking my questions and congrats on all the progress. So looking forward to next data from the program -- from the MARIO-1 program, how should we be thinking about next medical meetings you might think about targeting for some more of this expansion data and kind of the scope of a potential update we could see maybe in 2019? And then maybe on the MARIO-3 trial announced this morning. What are the gating factors to getting this trial started in the third quarter? I'm curious how you are thinking about timeline for enrollment, potential synergies with other trials? Thanks so much, guys.

Adelene Perkins

Thanks, Tessa. So MARIO-1 as we mentioned in the prepared remarks is continuing to mature. And any updates on data from next will be driven by the relevance to our existing studies MARIO-3, MARIO-275 or to the extent that they inform a new study that we want to initiate. And so we'll continue to monitor that data and to the extent that it applies to our going forward development we are reporting the data. In many ways MARIO-1 has already delivered what we hoped and it showed that IPI-549 is very well tolerated, is active. And it was a key to driving based on the triple negative activity we saw with MARIO-3 collaboration, as well as based on the MDSC results, the CheckMate 275.

With respect to any updates on MARIO-3, as well as our other study, we'll provide more granular guidance on the timing for enrollment in data, once we have more information on the enrollment kinetics as those studies are initiated later this year. And the team -- there's really nothing that’s gating to us going. The team is forging ahead working with our CRO selecting sites and are very aggressive and optimistic about our ability to get that up and going in the third quarter.

Lawrence Bloch

Right after this call, we are going to cut loose Sam to go and kick-off meeting for the trial today. So we're absolutely focused on execution.

Operator

Thank you. [Operator Instructions]. And I'm showing no further questions at this time. I’d like to turn the conference back over to Adelene Perkins for closing remarks.

Adelene Perkins

Thank you. And thank you everyone for joining us this morning. We're very excited about the opportunity we have with IPI-549 and we look forward to updating you on our progress throughout the year. So have a good day, everyone. And thank you for joining us.

Operator

Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program. And you may all disconnect. Everyone, have a great day.